2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 370

Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Abstract Number: 2832

Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target
Abstract Number: 1860

Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study
Abstract Number: 2410

Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable
Abstract Number: 1906

Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)
Abstract Number: 1246

Using PROMIS Data to Assess Activity of Inflammatory Eye Disease
Abstract Number: 1539

Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study
Abstract Number: 1837

Ustekinumab for the Treatment of Giant Cell Arteritis
Abstract Number: 662

Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Abstract Number: 407

Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Abstract Number: 1165

Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review
Abstract Number: 212

Utility of Mood Disorders Questionnaire in Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry
Abstract Number: 303

Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission
Abstract Number: 1802

Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics
Abstract Number: 665

Utility of Repeat Renal Biopsies in Patients with Lupus Nephritis in Western Australia

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].